Evidence map›Paper›PMID 41522810›Full record

ArticleNAR cancer2026

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes.

Collin D Heer, James L Elia, Vijay Menon, Spenser S Johnson, Sofia R Arbelaez, Sam Friedman, Francesc Lopez-Giraldez, Ranjini K Sundaram, Seth B Herzon, Ranjit S Bindra and 1 more

Abstract read
In one paragraph

Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Collin D HeerDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.ORCID 0000-0002-9005-3979
James L EliaDepartment of Pathology, Yale University, New Haven, CT 06510, United States.
Vijay MenonDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.
Spenser S JohnsonDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.
Sofia R ArbelaezDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.
Sam FriedmanDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.
Francesc Lopez-GiraldezDepartment of Genetics, Yale University, New Haven, CT 06510, United States.
Ranjini K SundaramDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.
Seth B HerzonDepartment of Chemistry, Yale University, New Haven, CT 06510, United States.
Ranjit S BindraDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.ORCID 0000-0002-3255-0467
Susan E GuebleDepartment of Therapeutic Radiology, Yale University, New Haven, CT 06510, United States.ORCID 0000-0002-8043-1147

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9M
Therapy Evaluation CoreU19CA264362 · NCI · MAYO CLINIC ROCHESTER · PI SARKARIA, JANN N. · 2021 to 2025
$7.6M
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient CancerDP5OD036128 · OD · YALE UNIVERSITY · PI Susan E Gueble · 2023 to 2026
$2.1M
Cancer Bioinformatics: Data analysis and method development for the Yale Cancer CenterR50CA265359 · NCI · YALE UNIVERSITY · PI Juan Francisco Lopez Giraldez · 2022 to 2026
$699k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA121974NCI NIH HHS R50 CA265359NCI NIH HHS U19 CA264362NIH HHS DP5 OD036128
6 · The paper itself

Abstract

Genetic instability is a hallmark of cancer, often arising from mutations to DNA damage repair and response (DDR) genes. Classical genetic, biochemical, and structural approaches elucidated the foundational mechanisms of DDR pathways and provided a scientific understanding of their involvement in repair of lesions induced by broad classes of DNA-damaging agents (DDAs). However, given the chemical diversity of DDAs and resultant DNA lesions, along with the multitude of interconnected DDR factors, the chemogenomic landscape of DDA-DDR interactions remains incompletely mapped. To this end, we developed a DDR-targeted, CRISPR knockout screening approach and assessed relationships amongst 353 DNA repair genes and 15 DDAs in LN229 glioma cells. Within this dataset of 5295 DDR-related chemogenomic interactions, we identified many established interactions and discovered novel ones. For example, we observed a specific role of transcription-coupled nucleotide excision repair in the repair of adducts generated by monofunctional alkylating agents, a role for the Fanconi anemia pathway in addressing methyl lesions, overt differences in DSB repair following treatment with topoisomerase I versus II poisons, and repair dependencies associated with the imidazotetrazines temozolomide, mitozolomide, and KL-50. Future directions will continue to investigate the mechanisms of novel chemogenomic interactions that we have uncovered as well as work to identify chemogenomic interactions amenable to clinical translation.

Indexed as

CRISPR-Cas SystemsDNA DamageDNA RepairGliomaCell Line, TumorExcision RepairGene Knockout TechniquesHumansTemozolomideTemozolomide

Identifiers

PMID41522810
PMCPMC12783042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.